A Clinical Trail of Integrative Medicine Approaches for Post-Stroke Cognitive Impairment
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: XINYUN LI, Master
- Phone Number: 8618069783240
- Email: lxyjasmine2010@163.com
Study Contact Backup
- Name: RUIJIE MA, Doctor
Study Locations
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310000
- The Third Affiliated hospital of Zhejiang Chinese Medical University
-
Hangzhou, Zhejiang, China, 310002
- Hangzhou Hospital of Traditional Chinese Medicine
-
Jiaxing, Zhejiang, China, 314000
- Jiaxing hospital of Chinese traditional medicine
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Stroke as per the TCM definition, presenting symptoms include unilateral paresis or paralysis, sensory deficits, speech impairment, and hemianopsia. PSCI diagnosis involves clinically significant deficits in at least one cognitive domain and severe disruption of instrumental activity of daily livings.
- age above 18 years;
- disease duration of 30-180 days;
- written informed consent by the patient's legal guardian;
- MoCA (Montreal Cognitive Assessment) score of 17-26. If patient was educated for ≤ 12 years, one score will be deducted;
- HAMD(Hamilton Depression Scale) score < 20;
- indications for acupuncture and moxibustion techniques.
Exclusion Criteria:
- Cognitive impairment caused by subarachnoid hemorrhage, transient ischemic attack, or other intracranial lesions., such as tumors, aneurysms, vascular malformations, cysticercosis, schistosomiasis, encephalitis, meningitis, hydrocephalus, or head trauma;
- non-atherosclerotic thrombotic cerebral infarction (such as cardiac embolism, procoagulant state, endovascular shedding, or arteritis);
- pregnant or lactating women;
- severe chronic diseases of the heart, liver, kidneys, other viscera, or endocrine system or hematopoietic system;
- severe dementia, serious language understanding disorders, or mental illness;
- bleeding tendency;
- lack of inclusion criteria or not suitable for clinical observation.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
No Intervention: control
standard treatment
|
|
|
Experimental: treatment
standard treatment, regular cognitive function training, acupuncture, and herbs
|
Chinese traditional rehabilitation including acupuncture and herbs
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change of Cognitive function
Time Frame: 0 week, 4 weeks, 8 weeks, 12 weeks, 16weeks
|
Montreal Cognitive Assessment(MOCA) will be used, this method focus on the sensitivity and specificity of the scale for the recognition of cognitive impairment are high, and it is evaluated from visual spatial/executive function, language function, image ability orientation and so on.
MoCA has a maximum score of 30 points.
The normal scoring standard is a total score ≥ 26 points (for those with an education level ≤ 12 years, this standard is reduced by 1 point).
Higher scores mean a better outcome.
|
0 week, 4 weeks, 8 weeks, 12 weeks, 16weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Changes in the patterns of activation of brain regions related to cognitive impairment
Time Frame: 0 weeks, 8 weeks
|
ALLF, fALFF, PerAF, ReHo and DC were used to analyze the resting state functional magnetic resonance imaging.
The pattern changes of relevant brain regions related to cognitive impairment after stroke were revealed.
|
0 weeks, 8 weeks
|
|
change in the scores of mini-Mental State Examination (MMSE)
Time Frame: 0 week, 8 weeks, 12 weeks, 16 weeks
|
The scale is used for rapid evaluation of orientation, memory, attention, calculation, language, and visuospatial structure.
MMSE has a maximum score of 30 points.
The normal cut-off values are: illiterate group ≥17 points, primary school group ≥20 points, middle school or higher group ≥24 points.
Higher scores mean a better outcome.
|
0 week, 8 weeks, 12 weeks, 16 weeks
|
|
Changes in Daily Living ability
Time Frame: 0 week, 8 weeks, 12 weeks, 16 weeks
|
ADL(Activity of Daily Living) will be used, which also known as the Barthel Index, consists of 10 items, including toileting, grooming, using the toilet, eating, dressing, transferring, activities, going up and down stairs, and bathing).
The total score ranges from 0 to 100.
Higher scores mean a better outcome.
|
0 week, 8 weeks, 12 weeks, 16 weeks
|
|
Changes in depressive status
Time Frame: 0 week, 8 weeks, 12 weeks and 16 weeks
|
use Hamilton Depression Scale to evaluate depression, the score were 24 for severe, 17 for moderate and 7 for mild.
Higher scores mean a worse outcome.
|
0 week, 8 weeks, 12 weeks and 16 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: RUIJIE MA, Doctor, The Third Affiliated hospital of Zhejiang Chinese Medical University
- Principal Investigator: XINYUN LI, Master, Zhejiang Chinese Medical University
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2020ZJZS002
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.